Delving into the Latest Updates on GP-6(Hartford Hospital) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

Bacterial DNA gyrase

Action

inhibitors

Mechanism

Bacterial DNA gyrase inhibitors(Bacterial DNA gyrase inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication-

Inactive Indication

Pseudomonas aeruginosa infection

Originator Organization

Hartford Hospital

Active Organization-

Inactive Organization

Hartford Hospital

License Organization-

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

The activity of five novel gyrase inhibitors was evaluated against 303 nonduplicate Pseudomonas aeruginosa strains collected from 53 North American institutions. The most active compound, GP-2, displayed MIC 50 and MIC 90 values of 1 and 2 μg/ml, respectively. Cross-resistance to other commercially available antipseudomonal compounds was not evident, as no major change was observed in the gyrase inhibitor MIC distribution when stratified by nonsusceptible phenotypes, including the fluoroquinolones and those isolates classified as multidrug resistant (MDR).

01 Jan 2012·Journal of pharmacy & bioallied sciences

Article

Author: Kamalesh Upreti ; Vinod Rana ; Kumud Upadhyaya ; Anjali Badhani ; Prashant Dabral

The intraocular patches were prepared using gelatin as the polymer. Ocular patch were prepared by solvent casting method. The patches were prepared for six formulations GP1, GP2, GP3, GP4, GP5 and GP6. Petri dishes were used for formulation of ocular patch. Gelatin was used as a polymer of choice. Glutaraldehyde used as cross linking agent and (DMSO) dimethylsulfoxide used as solubility enhancer. The elasticity depends upon the concentration of gelatin. 400 mg amount of polymer i.e gelatin gave the required elasticity for the formulation.

100 Deals associated with GP-6(Hartford Hospital)

Login to view more data